Literature DB >> 18349382

Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release.

Yuan Ji1, Eric M Snyder, Brooke L Fridley, Oreste E Salavaggione, Irene Moon, Anthony Batzler, Vivien C Yee, Daniel J Schaid, Michael J Joyner, Bruce D Johnson, Richard M Weinshilboum.   

Abstract

Phenylethanolamine N-methyltransferase (PNMT) catalyzes the synthesis of epinephrine from norepinephrine. We previously identified and functionally characterized common sequence variation in the PNMT gene. In the present study, we set out to determine whether common PNMT genetic polymorphisms might be associated with individual variation in circulating epinephrine levels during exercise in 74 Caucasian American subjects. Circulating epinephrine levels were measured in each subject at baseline and during two different levels of exercise, approximately 40% and approximately 75% of peak workload. The PNMT gene was resequenced with DNA from each study subject. Eight novel PNMT polymorphisms were identified, including a C319T (Arg107Cys) nonsynonymous single nucleotide polymorphism (SNP) and I1G(280)A, a SNP located in the first intron of the gene. The I1G(280)A SNP was significantly associated with decreased exercise-induced circulating epinephrine levels and with a decreased epinephrine-to-norepinephrine ratio. The Cys107 recombinant allozyme displayed significantly lower levels of both PNMT activity and immunoreactive protein than the wild-type allozyme after transfection into COS-1 cells, but it did not appear to be associated with level of epinephrine in these subjects. Electrophoretic mobility shift and reporter gene assays performed with the I1G(280)A SNP indicated that this polymorphism could bind nuclear proteins and might modulate gene transcription. Our studies suggest that functionally significant variant sequence in the human PNMT gene might contribute to individual variation in levels of circulating epinephrine during exercise.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349382     DOI: 10.1152/physiolgenomics.00248.2007

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  5 in total

1.  Conserved regulatory motifs at phenylethanolamine N-methyltransferase (PNMT) are disrupted by common functional genetic variation: an integrated computational/experimental approach.

Authors:  Juan L Rodríguez-Flores; Kuixing Zhang; Sun Woo Kang; Gen Wen; Sajalendu Ghosh; Ryan S Friese; Sushil K Mahata; Shankar Subramaniam; Bruce A Hamilton; Daniel T O'Connor
Journal:  Mamm Genome       Date:  2010-03-05       Impact factor: 2.957

2.  Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise.

Authors:  Laxmi V Ghimire; Utkarsh Kohli; Chun Li; Gbenga G Sofowora; Mordechai Muszkat; Eitan A Friedman; Joseph F Solus; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

Review 3.  Epinephrine: a short- and long-term regulator of stress and development of illness : a potential new role for epinephrine in stress.

Authors:  Dona Lee Wong; T C Tai; David C Wong-Faull; Robert Claycomb; Edward G Meloni; Karyn M Myers; William A Carlezon; Richard Kvetnansky
Journal:  Cell Mol Neurobiol       Date:  2011-11-17       Impact factor: 5.046

4.  Phenylethanolamine N-methyltransferase gene polymorphisms associate with crisis pain in sickle cell disease patients.

Authors:  Nilanjana Sadhu; Ellie H Jhun; Andrew Posen; Yingwei Yao; Ying He; Robert E Molokie; Diana J Wilkie; Zaijie J Wang
Journal:  Pharmacogenomics       Date:  2020-03-12       Impact factor: 2.533

5.  Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target.

Authors:  Silvia Giatti; Alessandro Di Domizio; Silvia Diviccaro; Eva Falvo; Donatella Caruso; Alessandro Contini; Roberto Cosimo Melcangi
Journal:  J Med Chem       Date:  2021-04-12       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.